JP2024528195A5 - - Google Patents
Info
- Publication number
- JP2024528195A5 JP2024528195A5 JP2024506610A JP2024506610A JP2024528195A5 JP 2024528195 A5 JP2024528195 A5 JP 2024528195A5 JP 2024506610 A JP2024506610 A JP 2024506610A JP 2024506610 A JP2024506610 A JP 2024506610A JP 2024528195 A5 JP2024528195 A5 JP 2024528195A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- propylene glycol
- approximately
- liquid pharmaceutical
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21189990 | 2021-08-05 | ||
| EP21189990.1 | 2021-08-05 | ||
| PCT/EP2022/072049 WO2023012322A1 (en) | 2021-08-05 | 2022-08-05 | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528195A JP2024528195A (ja) | 2024-07-26 |
| JP2024528195A5 true JP2024528195A5 (https=) | 2025-08-01 |
Family
ID=77226756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506610A Pending JP2024528195A (ja) | 2021-08-05 | 2022-08-05 | ブラジキニンｂ２受容体拮抗薬を経口投与するための脂質ベースの組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20240350418A1 (https=) |
| EP (1) | EP4203919B1 (https=) |
| JP (1) | JP2024528195A (https=) |
| KR (1) | KR20240039185A (https=) |
| CN (1) | CN118076342B (https=) |
| AU (1) | AU2022323749A1 (https=) |
| BR (1) | BR112024002215A2 (https=) |
| CA (1) | CA3227476A1 (https=) |
| CO (1) | CO2024001171A2 (https=) |
| DK (1) | DK4203919T3 (https=) |
| ES (1) | ES2978563T3 (https=) |
| FI (1) | FI4203919T3 (https=) |
| HR (1) | HRP20240525T1 (https=) |
| HU (1) | HUE066306T2 (https=) |
| IL (1) | IL310321A (https=) |
| LT (1) | LT4203919T (https=) |
| MA (1) | MA61123B1 (https=) |
| MX (1) | MX2024001711A (https=) |
| PL (1) | PL4203919T3 (https=) |
| PT (1) | PT4203919T (https=) |
| RS (1) | RS65427B1 (https=) |
| SI (1) | SI4203919T1 (https=) |
| SM (1) | SMT202400157T1 (https=) |
| WO (1) | WO2023012322A1 (https=) |
| ZA (1) | ZA202401504B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2218554T3 (es) | 1994-10-27 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina. |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| JP2002517461A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ブラジキニンアンタゴニスト |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| WO2008055146A2 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Formulations of phospholipase enzyme inhibitors |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| WO2014159637A1 (en) | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Methods of treating b2-bradykinin receptor mediated angioedema |
| AR113839A1 (es) | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
-
2022
- 2022-08-05 MA MA61123A patent/MA61123B1/fr unknown
- 2022-08-05 IL IL310321A patent/IL310321A/en unknown
- 2022-08-05 KR KR1020247007280A patent/KR20240039185A/ko active Pending
- 2022-08-05 CN CN202280067108.5A patent/CN118076342B/zh active Active
- 2022-08-05 PT PT227609864T patent/PT4203919T/pt unknown
- 2022-08-05 HU HUE22760986A patent/HUE066306T2/hu unknown
- 2022-08-05 BR BR112024002215A patent/BR112024002215A2/pt unknown
- 2022-08-05 ES ES22760986T patent/ES2978563T3/es active Active
- 2022-08-05 FI FIEP22760986.4T patent/FI4203919T3/fi active
- 2022-08-05 AU AU2022323749A patent/AU2022323749A1/en active Pending
- 2022-08-05 SM SM20240157T patent/SMT202400157T1/it unknown
- 2022-08-05 SI SI202230031T patent/SI4203919T1/sl unknown
- 2022-08-05 CA CA3227476A patent/CA3227476A1/en active Pending
- 2022-08-05 RS RS20240456A patent/RS65427B1/sr unknown
- 2022-08-05 EP EP22760986.4A patent/EP4203919B1/en active Active
- 2022-08-05 PL PL22760986.4T patent/PL4203919T3/pl unknown
- 2022-08-05 LT LTEPPCT/EP2022/072049T patent/LT4203919T/lt unknown
- 2022-08-05 DK DK22760986.4T patent/DK4203919T3/da active
- 2022-08-05 MX MX2024001711A patent/MX2024001711A/es unknown
- 2022-08-05 WO PCT/EP2022/072049 patent/WO2023012322A1/en not_active Ceased
- 2022-08-05 HR HRP20240525TT patent/HRP20240525T1/hr unknown
- 2022-08-05 US US18/681,298 patent/US20240350418A1/en active Pending
- 2022-08-05 JP JP2024506610A patent/JP2024528195A/ja active Pending
-
2024
- 2024-02-05 CO CONC2024/0001171A patent/CO2024001171A2/es unknown
- 2024-02-20 ZA ZA2024/01504A patent/ZA202401504B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2196303T5 (es) | Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias. | |
| TWI285644B (en) | A stable pharmaceutical composition containing a derivative of 4,5-epoxymorphinan and a water-soluble antioxidant, an oil-soluble antioxidant, a synergist, a sugar and a surfactant | |
| ES2559475T3 (es) | Composiciones para tratar náuseas y vómitos de origen central | |
| BRPI0718497A2 (pt) | Cápsulas macias compreendendo cloridrato de palonosetrona com biodisponibilidade e estabilidade aperfeiçoadas | |
| US20160346235A1 (en) | Oral liquid compositions of guanfacine | |
| JP6603785B2 (ja) | 水溶性高分子を含む水性液剤 | |
| JPH0948728A (ja) | 解熱鎮痛剤 | |
| BR112020016500A2 (pt) | Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea | |
| CN108472252A (zh) | 赖诺普利制剂 | |
| CN1141937C (zh) | 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物 | |
| JP2022554276A5 (https=) | ||
| CN101854913A (zh) | 含有缬沙坦的液体组合物 | |
| JP2024528195A5 (https=) | ||
| JP5021887B2 (ja) | アゼチジン誘導体に基づく医薬組成物 | |
| AU2006249254A1 (en) | Combinations comprising COX-2 inhibitors and aspirin | |
| US20140309296A1 (en) | Budiodarone formulations | |
| US4937079A (en) | Pharmaceutical composition for the prophylaxis and therapy of gastric ulcer | |
| JP2004520398A (ja) | 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物 | |
| EP3288549A1 (en) | Oral liquid compositions of guanfacine | |
| EP0843998A1 (en) | Oral pharmaceutical composition having antipyretic, analgesic and antiinflammatory activity | |
| AP945A (en) | Encapsulated solution dosage forms of sertraline. | |
| HRP20240525T1 (hr) | Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora | |
| WO2025041166A1 (en) | Stable oral liquid formulations containing metoprolol or salts thereof | |
| JPH10298077A (ja) | 心筋症の治療、予防剤 | |
| Winniford et al. | Calcium antagonists in patients with cardiovascular disease: Current perspectives |